Coultreon Biopharma, a biotechnology firm focused on immunology, has successfully closed an oversubscribed $125 million Series A financing round. The funding, led by Sofinnova Investments with co-leads Forbion and Novo Holdings, is earmarked for advancing the company's lead candidate for autoimmune diseases. This capital infusion will propel the clinical development of COL-5671, a potential first-in-class oral therapy designed to address significant unmet medical needs.
A Strategic Investment for Autoimmune Innovation
The significant financing round attracted a syndicate of top-tier life science investors, underscoring strong confidence in Coultreon's platform. Maha Katabi of Sofinnova Investments praised the company's scientific depth, disciplined strategy, and the potential of its lead program. This robust backing positions Coultreon to address the significant unmet need for alternative oral treatments in autoimmune conditions where many patients struggle with existing options.
Targeting a Novel Inflammatory Pathway
Coultreon's therapeutic strategy is built upon more than fifteen years of dedicated research into salt-inducible kinases (SIKs). The company has identified SIK3 as a critical regulator of the signaling pathways that drive pathogenic immune responses. This focus allows for a differentiated and potentially more precise method for treating a wide range of autoimmune disorders by modulating key inflammatory processes.
Advancing the Lead Candidate COL-5671
The company's lead program, COL-5671, is a highly selective, oral SIK3 inhibitor designed for once-daily administration. Its unique mechanism works by reducing the production of key pro-inflammatory cytokines while simultaneously increasing an important immunoregulatory cytokine, IL-10. This dual action holds the promise of delivering broader and more durable disease control compared to currently available therapies.
Originally developed by Galapagos NV, ownership of the asset was fully transferred to Coultreon in April 2025 following an initial seed investment. Preclinical and early clinical data have shown that COL-5671 has favorable pharmacokinetics and a strong safety profile. These results support its continued development across several immune-mediated diseases, including Crohn's disease, psoriasis, and rheumatoid arthritis.
Clinical Development and Future Outlook
With the new capital, Coultreon plans to accelerate the clinical development of COL-5671, which is currently in Phase 1 studies. The company will initiate Phase 2 clinical trials for both psoriasis and ulcerative colitis. The goal is to achieve clinical proof-of-concept for the drug by 2027, a key milestone for the program and the company.
Pierre Raboisson, CEO of Coultreon Biopharma, described the financing as a major inflection point for the organization. He expressed pride in his team's achievements and affirmed the company's commitment to advancing its novel therapies to patients. The funding provides the necessary resources to unlock the broader potential of the company's entire development pipeline and scientific platform.
This substantial Series A financing round marks a pivotal moment for Coultreon Biopharma, validating its innovative approach to treating autoimmune diseases. The $125 million investment not only accelerates the development of COL-5671 but also signals strong investor belief in SIK3 inhibition as a transformative therapeutic strategy. For patients living with chronic inflammatory conditions, this progress represents a significant step toward a new generation of effective oral treatments.